IT was reported that the facility, which is now in operation, has 40 trained and qualified members comprising pathologists, scientists, medical technologists, bioinformaticians and software developers.
Is this true?
Verdict:
TRUE
The opening of the first central oncology laboratory for clinical trials in Malaysia, Hematogenix, is expected to move local pharmaceutical and healthcare industries further up the value chain into research and development (R&D) and related services.
Malaysian Investment Development Authority (Mida) deputy chief executive officer (Investment Development) Lim Bee Vian said the entry of Hematogenix in Malaysia is also expected to attract more global clinical trials into the country.
"This project with an investment of more than US$9mil (RM39mil) to date is made possible through our investment policies, incentives, talent development and availability, and facilitation in bringing in biological samples and machinery."
The opening of the laboratory, located in Cyberjaya, was launched by Health Minister Khairy Jamaluddin on Friday (July 22).
Khairy said that the collaboration would lead to more exchange of knowledge and training for scientists within the ministry as well as offer direct benefits for cancer patients, as various tests for cancer biomarkers are now available locally with a shorter waiting time for diagnosis.
Hematogenix is headquartered in Chicago, the United States, with three other branches globally, covering the European market in Manchester, United Kingdom; the China market in Shanghai; and the latest market for Asia Pacific in Cyberjaya.
Reference:
